Halozyme Therapeutics News
Baxter International Inc. and Halozyme Therapeutics, Inc., today announced that the European Commission has granted Baxter marketing authorization in all E
It's up, up, and away for these stocks
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhMay 17
An upcoming presentation at the American Society of Clinical Oncology excites Halozyme shareholders.
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual MeetingPR Newswire May 15
SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational ...